UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults

Expert opinion on pharmacotherapy, 2021-07, Vol.22 (10), p.1245-1251

Mesplède, Thibault

2021

Volltextzugriff (PDF)

Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update

Expert opinion on investigational drugs, 2018-12, Vol.27 (12), p.951-962

2018

Volltextzugriff (PDF)

HIV drug resistance against strand transfer integrase inhibitors

Retrovirology, 2017-06, Vol.14 (1), p.36-36, Article 36

2017

Volltextzugriff (PDF)

Antimalarial drugs and their metabolites are potent Zika virus inhibitors

Journal of medical virology, 2019-07, Vol.91 (7), p.1182-1190

2019

Volltextzugriff (PDF)

The antimalarial drug amodiaquine possesses anti‐ZIKA virus activities

Journal of medical virology, 2018-05, Vol.90 (5), p.796-802

2018

Volltextzugriff (PDF)

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

Journal of Virology, 2012-03, Vol.86 (5), p.2696-2705

2012

Volltextzugriff (PDF)

Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications

Expert opinion on pharmacotherapy, 2019-03, Vol.20 (4), p.385-397

2019

Volltextzugriff (PDF)

Diverse Types of Diterpenoids with an Aromatized C Ring from the Twigs of Podocarpus imbricatus

Journal of natural products (Washington, D.C.), 2020-08, Vol.83 (8), p.2416-2424

2020

Volltextzugriff (PDF)

Two Cases of Viral Re-suppression After M184V + R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification

Clinical infectious diseases, 2024-07, Vol.79 (1), p.198-201

2024

Volltextzugriff (PDF)

Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity

Journal of antimicrobial chemotherapy, 2016-08, Vol.71 (8), p.2083-2088

2016

Volltextzugriff (PDF)

Investigational drugs for HIV: trends, opportunities and key players

Expert opinion on investigational drugs, 2023-02, Vol.32 (2), p.127-139

2023

Volltextzugriff (PDF)

The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration

Antimicrobial agents and chemotherapy, 2023-05, Vol.67 (5), p.e0138622-e0138622

2023

Volltextzugriff (PDF)

Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase

Journal of virology, 2015-03, Vol.89 (6), p.3163-3175

2015

Volltextzugriff (PDF)

Combination therapies currently under investigation in phase I and phase II clinical trials for HIV-1

Expert opinion on investigational drugs, 2020-03, Vol.29 (3), p.273-283

2020

Volltextzugriff (PDF)

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors

Journal of antimicrobial chemotherapy, 2016-07, Vol.71 (7), p.1948-1953

2016

Volltextzugriff (PDF)

Differences among HIV-1 subtypes in drug resistance against integrase inhibitors

Infection, genetics and evolution, 2016-12, Vol.46, p.286-291

2016

Volltextzugriff (PDF)

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

Viruses, 2015-07, Vol.7 (7), p.3703-3718

2015

Volltextzugriff (PDF)

JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1

Journal of virology, 2017-05, Vol.91 (9)

2017

Volltextzugriff (PDF)

Where are we with injectables against HIV infection and what are the remaining challenges?

Expert review of anti-infective therapy, 2018-02, Vol.16 (2), p.143-152

2018

Volltextzugriff (PDF)

Investigational HIV integrase inhibitors in phase I and phase II clinical trials

Expert opinion on investigational drugs, 2017-11, Vol.26 (11), p.1207-1213

2017

Volltextzugriff (PDF)

The latest evidence for possible HIV-1 curative strategies

Drugs in Context, 2018, Vol.7, p.212522-14

2018

Volltextzugriff (PDF)

Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses

Retrovirology, 2016-04, Vol.13 (1), p.31-31, Article 31

2016

Volltextzugriff (PDF)

p53 Degradation Activity, Expression, and Subcellular Localization of E6 Proteins from 29 Human Papillomavirus Genotypes

Journal of Virology, 2012-01, Vol.86 (1), p.94-107

2012

Volltextzugriff (PDF)

Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity

Journal of virology, 2015-10, Vol.89 (20), p.10482-10488

2015

Volltextzugriff (PDF)

Evolution of HIV integrase resistance mutations

Current opinion in infectious diseases, 2013-02, Vol.26 (1), p.43-49

2013

Volltextzugriff (PDF)

1 – 25 von 122

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(119)
Mit Volltextzugriff
(110)

Publikationsform

Artikel
(121)
Buchkapitel
(1)

Sprache

Englisch
(120)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(95)
Life Sciences & Biomedicine
(92)
Humans
(74)
Virology
(42)
Human Immunodeficiency Virus
(38)
Hiv
(36)
Infectious Diseases
(35)
Hiv-1 - Drug Effects
(32)
Hiv-1 - Genetics
(32)
Microbiology
(32)
Hiv Integrase - Genetics
(31)
Heterocyclic Compounds, 3-Ring - Pharmacology
(30)
Pharmacology & Pharmacy
(30)
Drug Resistance, Viral
(29)
Hiv Integrase Inhibitors - Pharmacology
(29)
Hiv Infections - Drug Therapy
(28)
Drug Resistance
(26)
Hiv Infections - Virology
(26)
Mutation
(26)
Hiv-1 - Enzymology
(24)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults

Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update

HIV drug resistance against strand transfer integrase inhibitors

Antimalarial drugs and their metabolites are potent Zika virus inhibitors

The antimalarial drug amodiaquine possesses anti‐ZIKA virus activities

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications

Diverse Types of Diterpenoids with an Aromatized C Ring from the Twigs of Podocarpus imbricatus

Two Cases of Viral Re-suppression After M184V + R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification

Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity

Investigational drugs for HIV: trends, opportunities and key players

The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration

Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase

Combination therapies currently under investigation in phase I and phase II clinical trials for HIV-1

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors

Differences among HIV-1 subtypes in drug resistance against integrase inhibitors

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1

Where are we with injectables against HIV infection and what are the remaining challenges?

Investigational HIV integrase inhibitors in phase I and phase II clinical trials

The latest evidence for possible HIV-1 curative strategies

Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses

p53 Degradation Activity, Expression, and Subcellular Localization of E6 Proteins from 29 Human Papillomavirus Genotypes

Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity

Evolution of HIV integrase resistance mutations

Suchergebnisse filtern